<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553785</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-0056</org_study_id>
    <nct_id>NCT02553785</nct_id>
  </id_info>
  <brief_title>Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy</brief_title>
  <acronym>ReviventTC1</acronym>
  <official_title>Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVentrix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioVentrix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, prospective, single-armed, study designed to evaluate the&#xD;
      safety and efficacy of the BioVentrix Revivent TransCatheter (TC) System for left ventricular&#xD;
      (LV) volume reduction in heart failure (HF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective, single-armed, multi-center clinical trial is to further&#xD;
      establish the feasibility of using the BioVentrix Revivent TC System for the treatment of&#xD;
      left ventricular dysfunction in appropriate cohorts of humans suffering from heart failure.&#xD;
&#xD;
      The objective of this study is to determine the safety and functionality of a device that&#xD;
      enables left ventricle (LV) volume and radius reduction through scar exclusion in appropriate&#xD;
      patients suffering from systolic HF. Use of this device replicates the geometric&#xD;
      reconfiguration of the ventricle achieved through surgical Left Ventricular Reconstruction&#xD;
      (LVR), but on a beating heart, and creates the option of eliminating the use of&#xD;
      Cardiopulmonary Bypass.&#xD;
&#xD;
      The System utilizes anchors that are implanted into the scarred portion of the heart,&#xD;
      rendering the ventricle smaller, and is employed in a cardiac surgical setting without the&#xD;
      use of cardiopulmonary bypass. The Revivent TC anchors may be implanted through a sternotomy&#xD;
      or through a mini-thoracotomy and jugular access. Eligible subjects will be limited to those&#xD;
      whose ventricular dysfunction is due to ischemic cardiomyopathy caused, by a previous&#xD;
      (greater than 90 days) myocardial infarction (MI) with acontractile (akinetic and/or&#xD;
      dyskinetic) scar located in the antero-septal, apical (may extend laterally) region.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Overall rate of serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Decrease in LV volume (left ventricular end-systolic volume index) compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of Serious Adverse Device Effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Left Ventricular Ejection Fraction compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Hospital readmission for Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in NYHA failure class compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in a standardized 6-minute corridor walk test compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Quality of Life (QOL) by Minnesota Living with Heart Failure (MLHF) Questionnaire compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Revivent TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical treatment of left ventricle using the Revivent TC System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revivent TC</intervention_name>
    <arm_group_label>Revivent TC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 80;&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &gt;15% and ≤ 45%;&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Class II-IV;&#xD;
&#xD;
          -  Left Ventricular End Systolic Volume (LVESVI) ≥60 cc/m² but ≤ 120 cc/ m²&#xD;
&#xD;
          -  Contiguous acontractile (akinetic and/or dyskinetic) scar located in the&#xD;
             antero-septal, apical (may extend laterally) regions of the left ventricle as&#xD;
             evidenced by a Cardiac Magnetic Resonance (CMR) or Computed Tomography (CT);&#xD;
&#xD;
          -  Maintained standard medical management for at least 90 days, and at stable target (or&#xD;
             maximum tolerated) dosages;&#xD;
&#xD;
          -  Willing and competent to complete informed consent;&#xD;
&#xD;
          -  Viability of myocardium in regions remote from area of intended scar exclusion as&#xD;
             evidenced by CMR or CT;&#xD;
&#xD;
          -  Agree to required follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Calcified ventricular wall in the area of intended scar exclusion as verified by&#xD;
             echocardiography or equivalent;&#xD;
&#xD;
          -  Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by&#xD;
             echocardiography or equivalent;&#xD;
&#xD;
          -  Cardiac Resynchronization Therapy (CRT) device placement ≤ 60 days prior to&#xD;
             enrollment;&#xD;
&#xD;
          -  Significant diastolic dysfunction, defined as a pseudo-normal Doppler filling pattern&#xD;
             with E/A ratio &gt; 2;&#xD;
&#xD;
          -  Thin walled, paradoxically moving septal scar that would preclude successful support&#xD;
             of the anchor pairs as evidenced by CMR;&#xD;
&#xD;
          -  Cardiac valve disease which, in the opinion of the investigator, will require surgery;&#xD;
&#xD;
          -  Intolerance or unwillingness to take anti-coagulation medication;&#xD;
&#xD;
          -  Functioning pacemaker leads in antero-apical right ventricle, which, in the opinion of&#xD;
             the investigator, would interfere with anchor placement;&#xD;
&#xD;
          -  Pulmonary Arterial Pressure &gt; 60 mm Hg via echo;&#xD;
&#xD;
          -  Myocardial Infarction within 90 days prior to enrollment;&#xD;
&#xD;
          -  Previous Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) which&#xD;
             resulted, in the opinion of the investigator, in a significant residual neurological&#xD;
             deficit;&#xD;
&#xD;
          -  Aorto iliac disease that would preclude fem-fem bypass.&#xD;
&#xD;
          -  Previous right neck surgery, previous pericardiotomy, previous left chest surgery;&#xD;
&#xD;
          -  Co-morbid disease process with life expectancy of less than one year;&#xD;
&#xD;
          -  Patients with lung, kidney and/or liver transplant;&#xD;
&#xD;
          -  Chronic renal failure with a serum creatinine &gt;2 mg/dL;&#xD;
&#xD;
          -  Inoperable coronary disease with significant ischemia;&#xD;
&#xD;
          -  Pregnant or planning to become pregnant during the study;&#xD;
&#xD;
          -  Enrolled in any concurrent study other than observational.&#xD;
&#xD;
          -  Previous left thoracotomy&#xD;
&#xD;
          -  Pulmonary disease that would preclude single lung ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clinic University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bioventrix.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BioVentrix</keyword>
  <keyword>Revivent</keyword>
  <keyword>Revivent TC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

